Carrie E. Flanagan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carrie E. Flanagan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Badi El Osta
Atlanta VA Medical Center, Atlanta VA Health Care System, 1670 Clairmont Road, Decatur, GA 30033, USA
1 shared publication - Gee Young Lee
Department of Surgery, Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA 30310, USA
1 shared publication - Hadiyah-Nicole Green
Department of Surgery, Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA 30310, USA
1 shared publication - Maya B. Cothran
Ora Lee Smith Cancer Research Foundation, Advanced Technology and Development Center, 75 5th Street NW, Atlanta, GA 30308, USA
1 shared publication - Merry E. Sebelik
Department of Otolaryngology, Emory University School of Medicine, 550 Peachtree Street NE, Atlanta, Georgia 30308
1 shared publication - Mohamed Mubasher
National Research Mentoring Network (NRMN) and RCMI Coordinating Center, Morehouse School of Medicine, Atlanta, GA 30310, USA
1 shared publication
Latest Publications
- 22 February 2025
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 13 (1) , 1-6
Rhinitis of Pregnancy and Hormonally Induced Rhinitis
- 22 February 2025
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 13 (1) , 1-6
Rhinitis of Pregnancy and Hormonally Induced Rhinitis
- Open Access
Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer
Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.
Open AccessAssessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer
Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.